Bilieye
Non-invasive Remotely Solution for Monitoring Jaundice in Newborns
Company Overview
Snapshot
Founded in May 2024 by Chen Binyamin, Bilieye operates with 1–10 employees. The company has raised $700K across one funding round, focusing on developing its non-invasive app for monitoring jaundice in newborns.
Business overview
Bilieye is revolutionizing neonatal care through a non-invasive app designed to remotely monitor bilirubin levels in newborns. The core technology allows parents and healthcare providers to use a smartphone photo of a baby's eyes to assess bilirubin, a key indicator for jaundice. This digital healthcare solution aims to replace traditional invasive blood tests, serving the digital medical diagnostics market within the Health Tech & Life Sciences sector, with a focus on babies and patients.
Company Intelligence Q&A
- What is Bilieye's primary focus?
- Bilieye focuses on redefining neonatal care by providing a non-invasive, remote solution for monitoring jaundice in newborns using a smartphone app.
- When was Bilieye founded?
- Bilieye was founded in May 2024.
- Who is a founder of Bilieye?
- Chen Binyamin is a co-founder of Bilieye.
- What is the total capital raised by Bilieye?
- Bilieye has raised a total of $700K.
- What is the current product stage of the Bilieye app?
- The Bilieye app is currently in the clinical trial product stage. The company aims to provide a safe, effective, and accessible alternative to traditional bilirubin monitoring.